Avid Bioservices Inc (CDMO)

[biopharm]

Great question (again) and PS Targeting is HUGE ....as for patent protection ? We have that under control

From dosage specific patents to new IIS ..I mean new combination patents to delivery method such as subcutaneous ...to NEW medical device to be used for drug delivery ...etc etc and all mixes in between ...patents for IP assets affiliated with PS Targeting is no problem

Varisacumab anti VEGF coming soon

A side note for all the CDMO manufacturing space that will be required ...how has BOD Mark Bamforth secured the contracts for Arranta at 650 Pleasant St Watertown MA and plan on running 2 -12 hour shifts they are proposing ....when he sits on Avid CDMO BOD and can't promise guarantees for full capacity and CDMO making deals with ThermoFisher

Looks like they don't want to spill the brand just yet about expansion of Avid ...or they are breaking the law using confidential data info etc to benefit themselves ...I say they will do the right thing

____

Extending the market exclusivity of therapeutic antibodies through dosage patents

...
...
Dosage patents are one way to extend the market exclusivity of an approved drug beyond the lifetime of the patent that protects the drug as such. Dosage patents may help to compensate the applicant for the long period where the active pharmaceutical ingredient as such is already under patent prosecution, but not on the market yet, due to lengthy development and approval procedures. This situation erodes part of the time the drug is marketed under patent protection. Dosage patents filed at a later date can provide remedy for this problem.
...
...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968089/


_____


Intravenous-to-Subcutaneous (IV-to-SC) Drug Migration Market, 2024

Dublin, March 20, 2019 (GLOBE NEWSWIRE) -- The "Intravenous-to-Subcutaneous Drug Repositioning" report has been added to ResearchAndMarkets.com's offering.

As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection.

While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering.
...
...

https://www.globenewswire.com/news-release/2019/03/20/1757985/0/en/Intravenous-to-Subcutaneous-IV-to-SC-Drug-Migration-Market-2024.html
_____


Laura Benjamin - CEO Oncologie Inc re: PS Targeting biomarkers Avid Bioservices CDMO

https://podcasts.apple.com/us/podcast/laura-benjamin-oncologie-part-of-the-nametag-series/id1088325796?i=1000450524353
______________

650 Pleasant St

PB-2019-05 SP
650 Pleasant Street
Demo 5,000 s.f. of existing building to construct new 15,700 s.f. addition for office, lab/manufacturing
PB Hearing
11/13/2019 New

https://www.watertown-ma.gov/748/Zoning-Relief-PetitionsCases

_____________

Arranta - 12 hour shifts

https://www.watertown-ma.gov/DocumentCenter/View/28260/06_Arranta-commitment-to-the-TDM-Regulations_Oct-8-2019